Connect with us

Australia

THC Global signs medicinal cannabis product supply deal with MGC Pharma

THC Global Group Ltd (ASX:THC) has signed a supply agreement for formulated medicinal cannabis products with MGC Pharmaceuticals Ltd (ASX:MXC).

Under the Agreement, MGC Pharma will provide THC with an immediate supplementary source of medicinal cannabis products, which will be packaged and made available to patients under the Canndeo brand.

THC expects to launch these products in Australia and New Zealand through Q1 2020.

THC chief executive officer Ken Charteris said: “Our agreement with MGC Pharma provides THC Global with an immediate extension of our Canndeo branded medicinal cannabis product range, as well as a pathway for further collaboration with MGC Pharma taking advantage of THC Globals Southport Facility – the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere – and MGC Pharmas Maltese facility.

“We look forward to taking advantage of our market development activities in Australia, New Zealand, Canada, and Asia as we launch this new product r..

THC Global Group Ltd (ASX:THC) has signed a supply agreement for formulated medicinal cannabis products with MGC Pharmaceuticals Ltd (ASX:MXC).

Under the Agreement, MGC Pharma will provide THC with an immediate supplementary source of medicinal cannabis products, which will be packaged and made available to patients under the Canndeo brand.

THC expects to launch these products in Australia and New Zealand through Q1 2020.

THC chief executive officer Ken Charteris said: “Our agreement with MGC Pharma provides THC Global with an immediate extension of our Canndeo branded medicinal cannabis product range, as well as a pathway for further collaboration with MGC Pharma taking advantage of THC Globals Southport Facility – the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere – and MGC Pharmas Maltese facility.

"We look forward to taking advantage of our market development activities in Australia, New Zealand, Canada, and Asia as we launch this new product range over the course of the next two months.”

Scaling up supply

The agreement also provides for MGC Pharma and THC to collaborate on the future supply of active pharmaceutical ingredients (API) extracts as well as other finished product, including from THCs Southport Facility.

Accessing an immediate supplementary source of medicinal cannabis products, enables THC to scale up its supply to patients quicker, and offer patients a broader initial product range under the Canndeo brand.

The agreement with MGC Pharma also provides THC with access to tetrahydrocannabinol (THC) containing formulatioRead More – Source

Continue Reading

Australia

Panoramic Resources maintains FY20 production guidance; takes steps to mitigate Covid-19 risks

Panoramic Resources Ltd (ASX:PAN) is continuing to operate the Savannah Nickel Mine to schedule and has maintained its financial year 2020 forecast production guidance.

The company is following all relevant government requirements and health department advice while seeking to maintain its operating capacity.

Panoramic has already put in place a significant range of measures targeted at minimising the risk of potential transmission of COVID-19.

These measures extend across the full scope of activities at the Savannah Nickel Mine and associated logistics chain, as well as within the companys corporate office.

Minimising impact on FIFO roster[hhmc]
About 25% of Panoramics total workforce (including contract personnel) at the Savannah Nickel Mine work on a fly-in fly-out (FIFO) basis from interstate.

Various initiatives are being pursued in order to minimise any impact of these restrictions on the Savannah FIFO roster, including utilisation of the potential exemptions for FIFO mine wo..

Panoramic Resources Ltd (ASX:PAN) is continuing to operate the Savannah Nickel Mine to schedule and has maintained its financial year 2020 forecast production guidance.

The company is following all relevant government requirements and health department advice while seeking to maintain its operating capacity.

Panoramic has already put in place a significant range of measures targeted at minimising the risk of potential transmission of COVID-19.

These measures extend across the full scope of activities at the Savannah Nickel Mine and associated logistics chain, as well as within the companys corporate office.

Minimising impact on FIFO roster


About 25% of Panoramics total workforce (including contract personnel) at the Savannah Nickel Mine work on a fly-in fly-out (FIFO) basis from interstate.

Various initiatives are being pursued in order to minimise any impact of these restrictions on the Savannah FIFO roster, including utilisation of the potential exemptions for FIFO mine workers and sourcing of alternative operating personnel from within Western Australia.

Some of the other measures include:

Continue Reading

Australia

European Metals agrees final terms for Cinovec investment with CEZ

European Metals Holdings Limited (LON:EMH) has reached a final agreement for Czech state power utility CEZ to take a 51% stake in the Cinovec lithium project.

The amended terms will see CEZ pay €29.1mln for its stake compared to the original proposal of €34mln.

CEZ also has two break points to withdraw from the project, which if triggered will see its investment returned minus €250,000 and costs,

The new terms provide sufficient funding for the next stage of the development of the project, Keith Coughlan, European Metals managing director said in a statement.

“Given the current uncertain state of global markets, it is particularly affirming for us to have a partner with the corRead More – Source

[contf]
[contfnew]

Proactiveinvestors
[contfnewc]
[contfnewc]

European Metals Holdings Limited (LON:EMH) has reached a final agreement for Czech state power utility CEZ to take a 51% stake in the Cinovec lithium project.

The amended terms will see CEZ pay €29.1mln for its stake compared to the original proposal of €34mln.

CEZ also has two break points to withdraw from the project, which if triggered will see its investment returned minus €250,000 and costs,

The new terms provide sufficient funding for the next stage of the development of the project, Keith Coughlan, European Metals managing director said in a statement.

“Given the current uncertain state of global markets, it is particularly affirming for us to have a partner with the corRead More – Source

Continue Reading

Australia

Imugene CEO Leslie Chong backs immuno-oncology strategy with further share purchase

Imugene Ltd (ASX:IMU) managing director and chief executive officer Leslie Chong has further demonstrated confidence in the companys immuno-oncology strategy by purchasing more shares.

Chong purchased 475,240 at 1.8 cents per share on March 16 and now holds 4,387,124 shares and 77,098,765 options.

PD1-Vaxx study[hhmc]
The companys PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.

The drug will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.

The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

HER-Vaxx trial[hhmc]
The HER-Vaxx trial is targeting HER-2 positive gastric cancer.

To date, the PhaseRead More – Source

[contf]
[contfnew]

Proactiveinvestors
[contfnewc]
[contfnewc]

Imugene Ltd (ASX:IMU) managing director and chief executive officer Leslie Chong has further demonstrated confidence in the companys immuno-oncology strategy by purchasing more shares.

Chong purchased 475,240 at 1.8 cents per share on March 16 and now holds 4,387,124 shares and 77,098,765 options.

PD1-Vaxx study


The companys PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.

The drug will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.

The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

HER-Vaxx trial


The HER-Vaxx trial is targeting HER-2 positive gastric cancer.

To date, the PhaseRead More – Source

Continue Reading

Trending